Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7-day oral rivaroxaban study in infants under 6 months with thrombosis
NL-OMON44043Phase 2Withdrawn
- Sponsor
- Bayer
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in thrombosis, sponsored by Bayer. Primary endpoint: Pharmacokinetic/pharmacodynamic profile. Planned start Mar 2015; status: withdrawn.
02
Drugs
rivaroxaban
03
Conditions
thrombosis
Beyond the preview
Go deeper on NL-OMON44043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44043.